Highlights of weekly biotech stock moves

GenVec Inc. (NASDAQ:GNVC) lost a penny to $2.48 last week after the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) granted conditional approval for the biotech's first approved product, a foot-and-mouth disease vaccine for use in cattle.

Nektar Therapeutics (NASDAQ:NKTR) gained $0.82 (13%) to $7.35 last week after FDA granted Fast Track designation to NKTR-181 to treat moderate to severe chronic pain. The company plans to start Phase II testing of the mu opioid receptor agonist next month...